APO Research
Talk to an analyst

APO RESEARCH · REPORT

VEGF Inhibitor Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global VEGF Inhibitor Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026193 pages

Choose your research edition.

Industry ResearchVEGF Inhibitor Drugs Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal VEGF Inhibitor Drugs Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal VEGF Inhibitor Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal VEGF Inhibitor Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal VEGF Inhibitor Drugs Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global VEGF Inhibitor Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for VEGF Inhibitor Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for VEGF Inhibitor Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for VEGF Inhibitor Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for VEGF Inhibitor Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of VEGF Inhibitor Drugs include Sanofi, Novartis AG, Merck & Co., Inc., Eli Lilly & Company, Pfizer, GlaxoSmithKline plc, Bayer AG, Genentech, Inc. (Roche) and Bristol-Myers-Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global VEGF Inhibitor Drugs market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of VEGF Inhibitor Drugs and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents VEGF Inhibitor Drugs revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the VEGF Inhibitor Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

VEGF Inhibitor Drugs Segment by Company

Sanofi

Novartis AG

Merck & Co., Inc.

Eli Lilly & Company

Pfizer

GlaxoSmithKline plc

Bayer AG

Genentech, Inc. (Roche)

Bristol-Myers-Squibb Company

AstraZeneca plc

VEGF Inhibitor Drugs Segment by Type

Tyrosine Kinase Inhibitors

Monoclonal Antibodies

Others

VEGF Inhibitor Drugs Segment by Application

Oncology

Ophthalmology

Others

VEGF Inhibitor Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global VEGF Inhibitor Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of VEGF Inhibitor Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of VEGF Inhibitor Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of VEGF Inhibitor Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global VEGF Inhibitor Drugs industry.

Chapter 3: Detailed analysis of VEGF Inhibitor Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, VEGF Inhibitor Drugsrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global VEGF Inhibitor Drugs Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Tyrosine Kinase Inhibitors Table 3. Key Players of Monoclonal Antibodies Table 4. Key Players of Others Table 4. Global VEGF Inhibitor Drugs Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Oncology Table 6. Key Players of Ophthalmology Table 7. Key Players of Others Table 8. Global VEGF Inhibitor Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 9. Global VEGF Inhibitor Drugs Market Size by Region (2021-2026) & (US$ Million) Table 10. Global VEGF Inhibitor Drugs Market Share by Region (2021-2026) Table 11. Global VEGF Inhibitor Drugs Market Size by Region (2027-2032) & (US$ Million) Table 12. Global VEGF Inhibitor Drugs Market Share by Region (2027-2032) Table 13. VEGF Inhibitor Drugs Industry Trends Table 14. VEGF Inhibitor Drugs Industry Drivers Table 15. VEGF Inhibitor Drugs Industry Opportunities and Challenges Table 16. VEGF Inhibitor Drugs Industry Restraints Table 17. Global VEGF Inhibitor Drugs Revenue by Company (US$ Million) & (2021-2026) Table 18. Global VEGF Inhibitor Drugs Revenue Market Share by Company (2021-2026) Table 19. Global VEGF Inhibitor Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 20. Global VEGF Inhibitor Drugs Key Company Head Office and Area Served Table 21. Global VEGF Inhibitor Drugs Company, Product Type & Application Table 22. Global VEGF Inhibitor Drugs Company Establishment Date Table 23. Global Company Market Concentration Ratio (CR5 and HHI) Table 24. Global VEGF Inhibitor Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 25. Global VEGF Inhibitor Drugs Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global VEGF Inhibitor Drugs Market Size by Type (2021-2026) & (US$ Million) Table 27. Global VEGF Inhibitor Drugs Market Size by Type (2027-2032) & (US$ Million) Table 28. Global VEGF Inhibitor Drugs Revenue Market Share by Type (2021-2026) Table 29. Global VEGF Inhibitor Drugs Revenue Market Share by Type (2027-2032) Table 30. Global VEGF Inhibitor Drugs Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global VEGF Inhibitor Drugs Market Size by Application (2021-2026) & (US$ Million) Table 32. Global VEGF Inhibitor Drugs Market Size by Application (2027-2032) & (US$ Million) Table 33. Global VEGF Inhibitor Drugs Revenue Market Share by Application (2021-2026) Table 34. Global VEGF Inhibitor Drugs Revenue Market Share by Application (2027-2032) Table 35. Sanofi Company Information Table 36. Sanofi Business Overview Table 37. Sanofi VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Sanofi VEGF Inhibitor Drugs Product Portfolio Table 39. Sanofi Recent Development Table 40. Novartis AG Company Information Table 41. Novartis AG Business Overview Table 42. Novartis AG VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Novartis AG VEGF Inhibitor Drugs Product Portfolio Table 44. Novartis AG Recent Development Table 45. Merck & Co., Inc. Company Information Table 46. Merck & Co., Inc. Business Overview Table 47. Merck & Co., Inc. VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Merck & Co., Inc. VEGF Inhibitor Drugs Product Portfolio Table 49. Merck & Co., Inc. Recent Development Table 50. Eli Lilly & Company Company Information Table 51. Eli Lilly & Company Business Overview Table 52. Eli Lilly & Company VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Eli Lilly & Company VEGF Inhibitor Drugs Product Portfolio Table 54. Eli Lilly & Company Recent Development Table 55. Pfizer Company Information Table 56. Pfizer Business Overview Table 57. Pfizer VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Pfizer VEGF Inhibitor Drugs Product Portfolio Table 59. Pfizer Recent Development Table 60. GlaxoSmithKline plc Company Information Table 61. GlaxoSmithKline plc Business Overview Table 62. GlaxoSmithKline plc VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. GlaxoSmithKline plc VEGF Inhibitor Drugs Product Portfolio Table 64. GlaxoSmithKline plc Recent Development Table 65. Bayer AG Company Information Table 66. Bayer AG Business Overview Table 67. Bayer AG VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Bayer AG VEGF Inhibitor Drugs Product Portfolio Table 69. Bayer AG Recent Development Table 70. Genentech, Inc. (Roche) Company Information Table 71. Genentech, Inc. (Roche) Business Overview Table 72. Genentech, Inc. (Roche) VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Genentech, Inc. (Roche) VEGF Inhibitor Drugs Product Portfolio Table 74. Genentech, Inc. (Roche) Recent Development Table 75. Bristol-Myers-Squibb Company Company Information Table 76. Bristol-Myers-Squibb Company Business Overview Table 77. Bristol-Myers-Squibb Company VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Bristol-Myers-Squibb Company VEGF Inhibitor Drugs Product Portfolio Table 79. Bristol-Myers-Squibb Company Recent Development Table 80. AstraZeneca plc Company Information Table 81. AstraZeneca plc Business Overview Table 82. AstraZeneca plc VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. AstraZeneca plc VEGF Inhibitor Drugs Product Portfolio Table 84. AstraZeneca plc Recent Development Table 85. North America VEGF Inhibitor Drugs Market Size by Type (2021-2026) & (US$ Million) Table 86. North America VEGF Inhibitor Drugs Market Size by Type (2027-2032) & (US$ Million) Table 87. North America VEGF Inhibitor Drugs Market Size by Application (2021-2026) & (US$ Million) Table 88. North America VEGF Inhibitor Drugs Market Size by Application (2027-2032) & (US$ Million) Table 89. North America VEGF Inhibitor Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 90. North America VEGF Inhibitor Drugs Market Size by Country (2021-2026) Table 91. North America VEGF Inhibitor Drugs Market Size by Country (2027-2032) Table 92. Europe VEGF Inhibitor Drugs Market Size by Type (2021-2026) & (US$ Million) Table 93. Europe VEGF Inhibitor Drugs Market Size by Type (2027-2032) & (US$ Million) Table 94. Europe VEGF Inhibitor Drugs Market Size by Application (2021-2026) & (US$ Million) Table 95. Europe VEGF Inhibitor Drugs Market Size by Application (2027-2032) & (US$ Million) Table 96. Europe VEGF Inhibitor Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. Europe VEGF Inhibitor Drugs Market Size by Country (2021-2026) Table 98. Europe VEGF Inhibitor Drugs Market Size by Country (2027-2032) Table 99. China VEGF Inhibitor Drugs Market Size by Type (2021-2026) & (US$ Million) Table 100. China VEGF Inhibitor Drugs Market Size by Type (2027-2032) & (US$ Million) Table 101. China VEGF Inhibitor Drugs Market Size by Application (2021-2026) & (US$ Million) Table 102. China VEGF Inhibitor Drugs Market Size by Application (2027-2032) & (US$ Million) Table 103. Asia VEGF Inhibitor Drugs Market Size by Type (2021-2026) & (US$ Million) Table 104. Asia VEGF Inhibitor Drugs Market Size by Type (2027-2032) & (US$ Million) Table 105. Asia VEGF Inhibitor Drugs Market Size by Application (2021-2026) & (US$ Million) Table 106. Asia VEGF Inhibitor Drugs Market Size by Application (2027-2032) & (US$ Million) Table 107. Asia VEGF Inhibitor Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Asia VEGF Inhibitor Drugs Market Size by Country (2021-2026) Table 109. Asia VEGF Inhibitor Drugs Market Size by Country (2027-2032) Table 110. South America, Middle East & Africa VEGF Inhibitor Drugs Market Size by Type (2021-2026) & (US$ Million) Table 111. South America, Middle East & Africa VEGF Inhibitor Drugs Market Size by Type (2027-2032) & (US$ Million) Table 112. South America, Middle East & Africa VEGF Inhibitor Drugs Market Size by Application (2021-2026) & (US$ Million) Table 113. South America, Middle East & Africa VEGF Inhibitor Drugs Market Size by Application (2027-2032) & (US$ Million) Table 114. South America, Middle East & Africa VEGF Inhibitor Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. South America, Middle East & Africa VEGF Inhibitor Drugs Market Size by Country (2021-2026) Table 116. South America, Middle East & Africa VEGF Inhibitor Drugs Market Size by Country (2027-2032) Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. VEGF Inhibitor Drugs Product Image Figure 2. Global VEGF Inhibitor Drugs Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global VEGF Inhibitor Drugs Market Share by Type: 2025 VS 2032 Figure 4. Tyrosine Kinase Inhibitors Image Figure 5. Monoclonal Antibodies Image Figure 6. Others Image Figure 7. Global VEGF Inhibitor Drugs Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 8. Global VEGF Inhibitor Drugs Market Share by Application: 2025 VS 2032 Figure 9. Oncology Image Figure 10. Ophthalmology Image Figure 11. Others Image Figure 12. Global VEGF Inhibitor Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 14. Global VEGF Inhibitor Drugs Market Share by Region: 2025 VS 2032 Figure 15. Years Considered Figure 16. Global VEGF Inhibitor Drugs Market Share by Players in 2025 Figure 17. Global Top 5 and 10 VEGF Inhibitor Drugs Players Market Share by Revenue in 2025 Figure 18. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global VEGF Inhibitor Drugs Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global VEGF Inhibitor Drugs Revenue Market Share by Type (2021-2032) Figure 21. Global VEGF Inhibitor Drugs Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global VEGF Inhibitor Drugs Revenue Market Share by Application (2021-2032) Figure 23. North America VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 24. North America VEGF Inhibitor Drugs Market Share by Type (2021-2032) Figure 25. North America VEGF Inhibitor Drugs Market Share by Application (2021-2032) Figure 26. North America VEGF Inhibitor Drugs Market Share by Country (2021-2032) Figure 27. United States VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 28. Canada VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 29. Mexico VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 30. Europe VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 31. Europe VEGF Inhibitor Drugs Market Share by Type (2021-2032) Figure 32. Europe VEGF Inhibitor Drugs Market Share by Application (2021-2032) Figure 33. Europe VEGF Inhibitor Drugs Market Share by Country (2021-2032) Figure 34. Germany VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 35. France VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 36. U.K. VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 37. Italy VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 38. Russia VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 39. Nordic Countries VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 40. China VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 41. China VEGF Inhibitor Drugs Market Share by Type (2021-2032) Figure 42. China VEGF Inhibitor Drugs Market Share by Application (2021-2032) Figure 43. Asia VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 44. Asia VEGF Inhibitor Drugs Market Share by Type (2021-2032) Figure 45. Asia VEGF Inhibitor Drugs Market Share by Application (2021-2032) Figure 46. Asia VEGF Inhibitor Drugs Market Share by Country (2021-2032) Figure 47. Japan VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 48. South Korea VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 49. Taiwan VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 50. Southeast Asia VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 51. India VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 52. Australia VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa VEGF Inhibitor Drugs Market Share by Type (2021-2032) Figure 55. South America, Middle East & Africa VEGF Inhibitor Drugs Market Share by Application (2021-2032) Figure 56. South America, Middle East & Africa VEGF Inhibitor Drugs Market Share by Country (2021-2032) Figure 57. Brazil VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 58. South Africa VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 59. Saudi Arabia VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 60. Turkey VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 61. Argentina VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 62. UAE VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 63. Egypt VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 64. Chile VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 65. Research Process Figure 66. Key Executives Interviewed

Scope & coverage.

Types
  • Tyrosine Kinase Inhibitors
  • Monoclonal Antibodies
  • Others
Applications
  • Oncology
  • Ophthalmology
  • Others
Companies covered
  • Sanofi
  • Novartis AG
  • Merck & Co., Inc.
  • Eli Lilly & Company
  • Pfizer
  • GlaxoSmithKline plc
  • Bayer AG
  • Genentech, Inc. (Roche)
  • Bristol-Myers-Squibb Company
  • AstraZeneca plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global VEGF Inhibitor Drugs Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Tyrosine Kinase Inhibitors
  5. 1.2.3 Monoclonal Antibodies
  6. 1.2.4 Others
  7. 1.3 Market Analysis by Application
  8. 1.3.1 Global VEGF Inhibitor Drugs Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  9. 1.3.2 Oncology
  10. 1.3.3 Ophthalmology
  11. 1.3.4 Others
  12. 1.4 Global Market Growth Prospects
  13. 1.5 Global VEGF Inhibitor Drugs Growth Trends by Region
  14. 1.5.1 Global VEGF Inhibitor Drugs Market Size by Region: 2021 VS 2025 VS 2032
  15. 1.5.2 VEGF Inhibitor Drugs Market Size by Region (2021-2026)
  16. 1.5.3 VEGF Inhibitor Drugs Market Size by Region (2027-2032)
  17. 1.6 Assumptions and Limitations
  18. 1.7 Study Goals and Objectives
  19. 1.8 Years Considered
2 Global VEGF Inhibitor Drugs Market Dynamics
  1. 2.1 VEGF Inhibitor Drugs Industry Trends
  2. 2.2 VEGF Inhibitor Drugs Industry Drivers
  3. 2.3 VEGF Inhibitor Drugs Industry Opportunities and Challenges
  4. 2.4 VEGF Inhibitor Drugs Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global VEGF Inhibitor Drugs Revenue by Company (2021-2026)
  2. 3.2 Global VEGF Inhibitor Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global VEGF Inhibitor Drugs Key Company Head office and Area Served
  4. 3.4 Global VEGF Inhibitor Drugs Company, Product Type & Application
  5. 3.5 Global VEGF Inhibitor Drugs Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global VEGF Inhibitor Drugs Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 VEGF Inhibitor Drugs Players Market Share by Revenue in 2025
  9. 3.6.3 2025 VEGF Inhibitor Drugs Tier 1, Tier 2, and Tier 3
4 VEGF Inhibitor Drugs Market by Type
  1. 4.1 Global VEGF Inhibitor Drugs Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global VEGF Inhibitor Drugs Market Size by Type (2021-2032)
  3. 4.3 Global VEGF Inhibitor Drugs Market Size Share by Type (2021-2032)
5 VEGF Inhibitor Drugs Market by Application
  1. 5.1 Global VEGF Inhibitor Drugs Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global VEGF Inhibitor Drugs Market Size by Application (2021-2032)
  3. 5.3 Global VEGF Inhibitor Drugs Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Sanofi
  2. 6.1.1 Sanofi Company Information
  3. 6.1.2 Sanofi Business Overview
  4. 6.1.3 Sanofi VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Sanofi VEGF Inhibitor Drugs Product Portfolio
  6. 6.1.5 Sanofi Recent Developments
  7. 6.2 Novartis AG
  8. 6.2.1 Novartis AG Company Information
  9. 6.2.2 Novartis AG Business Overview
  10. 6.2.3 Novartis AG VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Novartis AG VEGF Inhibitor Drugs Product Portfolio
  12. 6.2.5 Novartis AG Recent Developments
  13. 6.3 Merck & Co., Inc.
  14. 6.3.1 Merck & Co., Inc. Company Information
  15. 6.3.2 Merck & Co., Inc. Business Overview
  16. 6.3.3 Merck & Co., Inc. VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Merck & Co., Inc. VEGF Inhibitor Drugs Product Portfolio
  18. 6.3.5 Merck & Co., Inc. Recent Developments
  19. 6.4 Eli Lilly & Company
  20. 6.4.1 Eli Lilly & Company Company Information
  21. 6.4.2 Eli Lilly & Company Business Overview
  22. 6.4.3 Eli Lilly & Company VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Eli Lilly & Company VEGF Inhibitor Drugs Product Portfolio
  24. 6.4.5 Eli Lilly & Company Recent Developments
  25. 6.5 Pfizer
  26. 6.5.1 Pfizer Company Information
  27. 6.5.2 Pfizer Business Overview
  28. 6.5.3 Pfizer VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Pfizer VEGF Inhibitor Drugs Product Portfolio
  30. 6.5.5 Pfizer Recent Developments
  31. 6.6 GlaxoSmithKline plc
  32. 6.6.1 GlaxoSmithKline plc Company Information
  33. 6.6.2 GlaxoSmithKline plc Business Overview
  34. 6.6.3 GlaxoSmithKline plc VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 GlaxoSmithKline plc VEGF Inhibitor Drugs Product Portfolio
  36. 6.6.5 GlaxoSmithKline plc Recent Developments
  37. 6.7 Bayer AG
  38. 6.7.1 Bayer AG Company Information
  39. 6.7.2 Bayer AG Business Overview
  40. 6.7.3 Bayer AG VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Bayer AG VEGF Inhibitor Drugs Product Portfolio
  42. 6.7.5 Bayer AG Recent Developments
  43. 6.8 Genentech, Inc. (Roche)
  44. 6.8.1 Genentech, Inc. (Roche) Company Information
  45. 6.8.2 Genentech, Inc. (Roche) Business Overview
  46. 6.8.3 Genentech, Inc. (Roche) VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Genentech, Inc. (Roche) VEGF Inhibitor Drugs Product Portfolio
  48. 6.8.5 Genentech, Inc. (Roche) Recent Developments
  49. 6.9 Bristol-Myers-Squibb Company
  50. 6.9.1 Bristol-Myers-Squibb Company Company Information
  51. 6.9.2 Bristol-Myers-Squibb Company Business Overview
  52. 6.9.3 Bristol-Myers-Squibb Company VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Bristol-Myers-Squibb Company VEGF Inhibitor Drugs Product Portfolio
  54. 6.9.5 Bristol-Myers-Squibb Company Recent Developments
  55. 6.10 AstraZeneca plc
  56. 6.10.1 AstraZeneca plc Company Information
  57. 6.10.2 AstraZeneca plc Business Overview
  58. 6.10.3 AstraZeneca plc VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 AstraZeneca plc VEGF Inhibitor Drugs Product Portfolio
  60. 6.10.5 AstraZeneca plc Recent Developments
7 North America
  1. 7.1 North America VEGF Inhibitor Drugs Market Size (2021-2032)
  2. 7.2 North America VEGF Inhibitor Drugs Market Size by Type
  3. 7.2.1 North America VEGF Inhibitor Drugs Market Size by Type (2021-2026)
  4. 7.2.2 North America VEGF Inhibitor Drugs Market Size by Type (2027-2032)
  5. 7.2.3 North America VEGF Inhibitor Drugs Market Share by Type (2021-2032)
  6. 7.3 North America VEGF Inhibitor Drugs Market Size by Application
  7. 7.3.1 North America VEGF Inhibitor Drugs Market Size by Application (2021-2026)
  8. 7.3.2 North America VEGF Inhibitor Drugs Market Size by Application (2027-2032)
  9. 7.3.3 North America VEGF Inhibitor Drugs Market Share by Application (2021-2032)
  10. 7.4 North America VEGF Inhibitor Drugs Market Size by Country
  11. 7.4.1 North America VEGF Inhibitor Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America VEGF Inhibitor Drugs Market Size by Country (2021-2026)
  13. 7.4.3 North America VEGF Inhibitor Drugs Market Size by Country (2027-2032)
  14. 7.4.4 North America VEGF Inhibitor Drugs Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe VEGF Inhibitor Drugs Market Size (2021-2032)
  2. 8.2 Europe VEGF Inhibitor Drugs Market Size by Type
  3. 8.2.1 Europe VEGF Inhibitor Drugs Market Size by Type (2021-2026)
  4. 8.2.2 Europe VEGF Inhibitor Drugs Market Size by Type (2027-2032)
  5. 8.2.3 Europe VEGF Inhibitor Drugs Market Share by Type (2021-2032)
  6. 8.3 Europe VEGF Inhibitor Drugs Market Size by Application
  7. 8.3.1 Europe VEGF Inhibitor Drugs Market Size by Application (2021-2026)
  8. 8.3.2 Europe VEGF Inhibitor Drugs Market Size by Application (2027-2032)
  9. 8.3.3 Europe VEGF Inhibitor Drugs Market Share by Application (2021-2032)
  10. 8.4 Europe VEGF Inhibitor Drugs Market Size by Country
  11. 8.4.1 Europe VEGF Inhibitor Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe VEGF Inhibitor Drugs Market Size by Country (2021-2026)
  13. 8.4.3 Europe VEGF Inhibitor Drugs Market Size by Country (2027-2032)
  14. 8.4.4 Europe VEGF Inhibitor Drugs Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China VEGF Inhibitor Drugs Market Size (2021-2032)
  2. 9.2 China VEGF Inhibitor Drugs Market Size by Type
  3. 9.2.1 China VEGF Inhibitor Drugs Market Size by Type (2021-2026)
  4. 9.2.2 China VEGF Inhibitor Drugs Market Size by Type (2027-2032)
  5. 9.2.3 China VEGF Inhibitor Drugs Market Share by Type (2021-2032)
  6. 9.3 China VEGF Inhibitor Drugs Market Size by Application
  7. 9.3.1 China VEGF Inhibitor Drugs Market Size by Application (2021-2026)
  8. 9.3.2 China VEGF Inhibitor Drugs Market Size by Application (2027-2032)
  9. 9.3.3 China VEGF Inhibitor Drugs Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia VEGF Inhibitor Drugs Market Size (2021-2032)
  2. 10.2 Asia VEGF Inhibitor Drugs Market Size by Type
  3. 10.2.1 Asia VEGF Inhibitor Drugs Market Size by Type (2021-2026)
  4. 10.2.2 Asia VEGF Inhibitor Drugs Market Size by Type (2027-2032)
  5. 10.2.3 Asia VEGF Inhibitor Drugs Market Share by Type (2021-2032)
  6. 10.3 Asia VEGF Inhibitor Drugs Market Size by Application
  7. 10.3.1 Asia VEGF Inhibitor Drugs Market Size by Application (2021-2026)
  8. 10.3.2 Asia VEGF Inhibitor Drugs Market Size by Application (2027-2032)
  9. 10.3.3 Asia VEGF Inhibitor Drugs Market Share by Application (2021-2032)
  10. 10.4 Asia VEGF Inhibitor Drugs Market Size by Country
  11. 10.4.1 Asia VEGF Inhibitor Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia VEGF Inhibitor Drugs Market Size by Country (2021-2026)
  13. 10.4.3 Asia VEGF Inhibitor Drugs Market Size by Country (2027-2032)
  14. 10.4.4 Asia VEGF Inhibitor Drugs Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa VEGF Inhibitor Drugs Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa VEGF Inhibitor Drugs Market Size by Type
  3. 11.2.1 South America, Middle East & Africa VEGF Inhibitor Drugs Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa VEGF Inhibitor Drugs Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa VEGF Inhibitor Drugs Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa VEGF Inhibitor Drugs Market Size by Application
  7. 11.3.1 South America, Middle East & Africa VEGF Inhibitor Drugs Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa VEGF Inhibitor Drugs Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa VEGF Inhibitor Drugs Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa VEGF Inhibitor Drugs Market Size by Country
  11. 11.4.1 South America, Middle East & Africa VEGF Inhibitor Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa VEGF Inhibitor Drugs Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa VEGF Inhibitor Drugs Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa VEGF Inhibitor Drugs Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst